HUM Stock Chart & Stats
$6766.67
$0.00(0.00%)
At close: 4:00 PM EDT
$6766.67
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,885.00 - $7,500.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
$798.22B
Enterprise Value$34.98K
Total Cash (Recent Filing)$23.87B
Total Debt (Recent Filing)$14.25B
Price to Earnings (P/E)41.4
Beta-0.31
Next Earnings
Nov 06, 2026EPS Estimate
-12.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.65
Shares Outstanding120,061,500
10 Day Avg. Volume1
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio-18.55
Price to Book (P/B)1.75
Price to Sales (P/S)0.24
P/FCF Ratio82.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6,534.77Price Target Upside-3.43% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)156.63
Revenue Forecast (FY)$2.83T
Bulls Say, Bears Say
Bulls Say
Durable Revenue Growth & MA ScaleConsistent mid-single-digit TTM revenue growth driven by Medicare Advantage and government products underpins scale and predictable capitated cash flows. That steadiness supports underwriting discipline, provider contracting leverage, and multi-quarter investment in CenterWell and care programs that improve long-term cost control.
Operational Cost Reductions And Margin RoadmapManagement’s execution on centralization, outsourcing, and vendor transformation has already produced meaningful G&A savings and hundreds of millions of dollars of value. Those structural cost moves should sustainably improve operating leverage and materially contribute to the multi-year path toward a targeted sustainable pretax MA margin.
Enhanced Liquidity & Capital FlexibilityPre-capitalized contingent facilities plus monetization of a non-core stake increase committed liquidity and optionality. This durable improvement in capital flexibility helps fund reserves, margin initiatives, and strategic expansion (e.g., Medicaid wins, CenterWell growth) while limiting forced balance-sheet moves under stress.
Bears Say
Compressed Profitability And Weak ROEMargins and returns have materially declined versus prior years, leaving a thin earnings cushion against medical cost shocks. Low profitability constrains internal reinvestment and shareholder returns, and increases sensitivity to reserve volatility and trend, making near-term margin recovery dependent on sustained operational wins.
Elevated Drug-Cost TrendPersistently high drug trend is a structural headwind for Part D and MA underwriting margins because drug inflation directly widens medical spend. With new drugs entering the market and limited short-term offsets, sustained elevated pharmacy trend will pressure margins and require either higher premiums, stronger rebates, or deeper medical offset.
Membership Disruption & Mix RiskLarge planned plan exits materially alter member composition and revenue base; recapture is uncertain and historically partial. Because MA profitability depends on risk-adjusted membership mix, this structural churn reduces visibility into near-term margins and could blunt the impact of cost initiatives if higher-cost cohorts dominate renewals.
Humana News
HUM FAQ
What was Humana Inc’s price range in the past 12 months?
Humana Inc lowest stock price was $2885.00 and its highest was $7500.00 in the past 12 months.
What is Humana Inc’s market cap?
Humana Inc’s market cap is $798.22B.
When is Humana Inc’s upcoming earnings report date?
Humana Inc’s upcoming earnings report date is Nov 06, 2026 which is in 99 days.
How were Humana Inc’s earnings last quarter?
Humana Inc released its earnings results on Jul 29, 2026. The company reported $132.722 earnings per share for the quarter, beating the consensus estimate of $126.705 by $6.017.
Is Humana Inc overvalued?
According to Wall Street analysts Humana Inc’s price is currently Overvalued.
Does Humana Inc pay dividends?
Humana Inc does not currently pay dividends.
What is Humana Inc’s EPS estimate?
Humana Inc’s EPS estimate is -12.03.
How many shares outstanding does Humana Inc have?
Humana Inc has 120,061,500 shares outstanding.
What happened to Humana Inc’s price movement after its last earnings report?
Humana Inc reported an EPS of $132.722 in its last earnings report, beating expectations of $126.705. Following the earnings report the stock price went up 5.044%.
Which hedge fund is a major shareholder of Humana Inc?
Currently, no hedge funds are holding shares in MX:HUM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humana Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6,534.77 (-3.43% Downside)
$6,534.77 (-3.43% Downside)
Blogger Sentiment
Bullish
MX:HUM Sentiment 88%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.30%
12-Months-Change
Fundamentals
Return on Equity
0.90%
Trailing 12-Months
Asset Growth
8.54%
Trailing 12-Months
Company Description
Humana Inc
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.
HUM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally constructive operational and strategic progress narrative: clear cost-reduction execution (120 bps Y/Y improvement in Q2 operating cost ratio and expected ~150 bps full-year), tangible improvement in key Stars-related measures (outperforming historical CAGR on most selected metrics and ~5% better quality improvement rate for BY '29 measures), balance-sheet moves (Gentiva divestiture ~ $900M and $1.5B P-Cap facilities) and a new statewide Medicaid win. However, material risks remain — notably elevated and rising drug trend, dependence on membership mix for margin realization, plan-exit disruption (~600k members), elevated reserves/IBNR, and Stars/ policy uncertainty — which temper the outlook. On balance, the highlights (execution, cost savings, Stars operational progress, capital actions) outweigh the lowlights (policy uncertainty, drug trend, membership disruption), producing a cautiously positive sentiment.View all MX:HUM earnings summariesHUM Revenue Breakdown
94.73% Premiums
4.50% Services
0.78% Investment income

HUM Stock 12 Month Forecast
Average Price Target
$6,534.77
▼(-3.43% Downside)











